Key result
Treating AF in HFpEF mitigates risk and improves outcomes, countering worsened symptom burden and prognosis.
Why the study?
Arrhythmias, particularly atrial fibrillation (AF), are common in HFpEF and complicate its diagnosis and management.
This review highlights the diagnostic challenges and therapeutic opportunities for managing atrial fibrillation in patients with heart failure with preserved ejection fraction.
May warrant AF evaluation in HFpEF; extends associations but leaves optimal strategies open for trials.
Heart failure with preserved ejection fraction (HFpEF) is a syndrome characterised by cardiac and non-cardiac physiologic disturbances, commonly underpinned by cardiometabolic abnormalities, which culminate in elevated left ventricular filling pressures and progressive symptoms of exercise intolerance. Arrhythmias, particularly atrial fibrillation (AF), are common in HFpEF and have important clinical implications. AF complicates the diagnosis and management of HFpEF. In this review, we synthesise the impact of AF on disease detection, symptom burden and prognosis and HFpEF treatment. Furthermore, we review pharmacological and interventional therapies that may mitigate the risk of AF and improve how patients with HFpEF feel, function and survive.
No takes yet. Share an insight, caveat, or question.
Verelst et al. (2026) studied this question. Atrial fibrillation complicates diagnosis and management of HFpEF, impacting symptom burden and prognosis, with therapies available to mitigate risk and improve outcomes.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: